COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VS SORAFENIB AND BEVACIZUMAB plus INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO

被引：1
|
作者：
Salinas-Escudero, G. [1 ]
Contreras-Hernandez, I [2 ]
Mould-Quevedo, J. [3 ]
机构：
[1] Hosp Infantil Mexico Fed Gomez, Mexico City, DF, Mexico
[2] Social Secur Mexican Inst, Mexico City, DF, Mexico
[3] Pfizer Mexico, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)75353-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A497 / A497
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VERSUS SORAFENIB AND BEVACIZUMAB plus INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN ECUADOR
    Torres Toala, F. G.
    Albuja Riofrio, M. F.
    Mould, J. F.
    Estevez, C.
    VALUE IN HEALTH, 2013, 16 (03) : A139 - A139
  • [2] COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB (SU) VS SORAFENIB (SFN) AND BEVACIZUMAB plus INTERFERON-ALFA (BEV/IFN) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN SPAIN
    Diaz, S.
    Aller, E. Calvo
    Maroto, P.
    Puente, J.
    Lopez-Brea, M.
    Castellano, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 227 - 227
  • [3] COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB plus INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN
    Remak, E.
    Vioix, H.
    Sandin, R.
    Harmenberg, U.
    Ullen, A.
    Sandstrom, P.
    VALUE IN HEALTH, 2009, 12 (07) : A270 - A270
  • [4] Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
    Pruis, Sil-ling
    Aziz, Mohamed Ismail Abdul
    Pearce, Fiona
    Tan, Min Han
    Wu, David Bin-Chia
    Ng, Kwong
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (02) : 126 - 133
  • [5] COST-EFFECTIVENESS ANALYSIS OF SUNITINIB VERSUS INTERFERON ALFA FOR THE FIRST-LINE TREATMENT OF ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA IN SINGAPORE
    Pruis, S.
    Pearce, F.
    Aziz, Abdul M., I
    Wu, D. B.
    Ng, K. H.
    VALUE IN HEALTH, 2018, 21 : S15 - S15
  • [6] COST-EFFECTIVENESS OF SUNITINIB (SU) VS SORAFENIB (SFN), TEMSIROLIMUS (TMS) AND BEVACIZUMAB plus INTERFERON-ALFA (BEV/IFN) AS FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC) - ADAPTATION FOR THE SWEDISH HEALTH SERVICE
    Munir, U.
    Benedict, A.
    Borgman, B.
    Sandin, R.
    Harmenberg, U.
    Ullen, A.
    Sandstrom, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 228 - 228
  • [7] First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
    Wan, XiaoMin
    Zhang, YuCong
    Tan, ChongQing
    Zeng, XiaoHui
    Peng, LiuBao
    JAMA ONCOLOGY, 2019, 5 (04) : 491 - 496
  • [8] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    JAMA NETWORK OPEN, 2021, 4 (02)
  • [9] Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma
    Wang, Siying
    Xie, Ouyang
    Wu, Meiyu
    Xiang, Heng
    Tan, Chongqing
    Wan, Xiaomin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 173 - 178
  • [10] Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan
    Al-Rabayah, Abeer A.
    Sawalha, Razan
    Al Froukh, Rawan Fawzi
    Al-Bawab, Rand
    Jaddoua, Saad M.
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (04) : 566 - 573
12345